TZ2 – GLP2 Research Overview: Dual GIP/GLP-1 Agonism (2026)

<p>TZ2 – GLP2 is a synthetic peptide that functions as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual mechanism of action distinguishes it structurally and pharmacologically from single-agonist GLP-1 receptor peptides and has generated significant interest in metabolic pathway research.</p><p>Developed by Eli Lilly and Company and approved by the FDA under the brand name Mounjaro (for type 2 diabetes) and Zepbound (for obesity) in 2022 and 2023 respectively, TZ2 – GLP2 as a research compound is studied in in-vitro and preclinical settings to understand the molecular mechanisms underlying its receptor interactions.</p><h2>Molecular Profile</h2><p>Molecular Formula: C225H348N48O68 | Molecular Weight: 4813.5 g/mol | CAS: 2023788-19-2</p><p>TZ2 – GLP2 consists of 39 amino acids with a C18 fatty diacid moiety attached via a linker to enable extended half-life through albumin binding — a structural feature that distinguishes it from earlier GLP-1 receptor agonists.</p><h2>Dual Receptor Mechanism: GIP and GLP-1</h2><h3>GLP-1 Receptor Pathway</h3><p>GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its receptor (GLP-1R) is expressed throughout the body including pancreatic beta cells, the central nervous system, and the gastrointestinal tract. Research has extensively characterized GLP-1R agonism as promoting glucose-dependent insulin secretion, reducing glucagon release, and slowing gastric emptying in multiple preclinical models.</p><h3>GIP Receptor Pathway</h3><p>GIP (glucose-dependent insulinotropic polypeptide) is secreted by duodenal K-cells. Its receptor (GIPR) is expressed in pancreatic beta cells, adipose tissue, bone, and brain regions. Historically considered a secondary incretin, the GIPR's role in energy metabolism has been significantly revised through research with compounds like TZ2 – GLP2. Studies have explored GIP's effect on adipose tissue lipid metabolism and its potential complementary role to GLP-1 in glucose homeostasis research.</p><h3>Combined Agonism Studies</h3><p>Research investigating TZ2 – GLP2's dual agonism has shown that simultaneous GIP and GLP-1 receptor engagement may produce additive or synergistic effects on glucose metabolism pathways compared to single-agonist models. Published clinical data from the SURPASS and SURMOUNT trial programs — while conducted as pharmaceutical trials rather than basic research — have provided quantitative data on the peptide's biological effects that inform laboratory model design.</p><p>↗ Willard et al. (2020). Small molecule drug discovery at the GLP-1 receptor. Experimental Diabetes Research. PubMed ID: 20617130</p><p>↗ Frias et al. (2021). TZ2 – GLP2 versus GLP-1 (S) Once Weekly in Patients with Type 2 Diabetes. NEJM. DOI: 10.1056/NEJMoa2107519</p><h2>Research Applications</h2><p>In laboratory research contexts, TZ2 – GLP2 is investigated to study:</p><ul><li>GIP and GLP-1 receptor co-activation mechanisms at the molecular level</li><li>Incretin signaling pathway interactions in cell culture models</li><li>Beta cell function and insulin secretion pathways in in-vitro models</li><li>Adipose tissue lipid metabolism pathway research</li><li>Central nervous system satiety signaling research</li><li>Comparative receptor binding studies vs. single-agonist GLP-1 compounds</li></ul><h2>Research Grade vs. Pharmaceutical Grade</h2><p>Research-grade TZ2 – GLP2 is synthesized for laboratory and analytical use only. It is not equivalent to pharmaceutical-grade Mounjaro or Zepbound. Research-grade material is verified by HPLC purity and mass spectrometry for identity and purity but is not manufactured under the same pharmaceutical GMP standards as FDA-approved drug products and is not sterile-tested or endotoxin-tested to pharmaceutical specifications. TX Research Peptides supplies TZ2 – GLP2 verified at ≥99% purity by independent third-party HPLC and mass spectrometry.</p><h2>Purity and Documentation Standards</h2><p>For TZ2 – GLP2 research, documentation requirements are elevated given the peptide's structural complexity (39 amino acids, fatty acid conjugate). Key verification requirements:</p><ul><li>HPLC purity ≥99% from an accredited external laboratory</li><li>LC-MS (liquid chromatography-mass spectrometry) confirming correct molecular weight (~4813.5 Da)</li><li>Batch-specific COA — not a generic document</li><li>Sequence confirmation documentation for complex peptides</li></ul><h2>Frequently Asked Questions</h2><p>Q: Is research-grade TZ2 – GLP2 the same as Mounjaro?</p><p>A: No. Research-grade TZ2 – GLP2 is produced for in-vitro laboratory use only. It is not a pharmaceutical product, not FDA-approved for research subjects, and not interchangeable with the prescription drug Mounjaro.</p><p>Q: What molecular weight should be confirmed by MS for TZ2 – GLP2?</p><p>A: The correct molecular weight is approximately 4813.5 g/mol. Mass spectrometry confirmation of this value verifies the correct sequence and conjugation.</p><p>Q: What is the difference between GLP-1 and GIP receptor agonism?</p><p>A: GLP-1R agonism primarily drives insulin secretion and gastric emptying delay. GIPR agonism additionally engages adipose tissue and bone metabolism pathways. TZ2 – GLP2 activates both simultaneously.</p><p>Q: How should TZ2 – GLP2 research peptide be stored?</p><p>A: Lyophilized at -20°C. Once reconstituted, maintain at 2–8°C and use promptly within your protocol window.</p><p>Related: TZ2 – GLP2 Product Page → | RT3 – GLP3 Research Guide → | GLP-1 (S) Research Guide → | Cagrilintide Research Guide →</p>